AbbVie Inc. (NYSE:ABBV) Stock Has Average Target Price of $279.86 According to Analysts

Shares of AbbVie Inc. (NYSE:ABBV) have earned an average rating of “Moderate Buy” from the thirty research firms that are presently covering the company, MarketBeat reports. Six research analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $279.86.

Several research analysts have recently weighed in on ABBV shares. Citigroup boosted their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. The Goldman Sachs Group raised their price objective on shares of AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a research report on Friday. Morgan Stanley lifted their target price on shares of AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Canaccord Genuity Group lifted their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, BNP Paribas Exane boosted their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved a subcutaneous induction regimen for AbbVie’s SKYRIZI in adults with moderately to severely active Crohn’s disease. The needle-based treatment option may improve convenience and support the drug’s continued growth across immunology indications. FDA approves subcutaneous SKYRIZI regimen
• Positive Sentiment: Goldman Sachs raised its price target for ABBV to $294, signaling continued confidence in the company’s outlook and providing a bullish valuation reference. Goldman Sachs raises AbbVie price target
• Positive Sentiment: Reports that Citadel has built an approximately $900 million position in AbbVie may boost sentiment by highlighting institutional interest in the company’s dividend and growth profile. Citadel AbbVie position
• Neutral Sentiment: Options markets imply roughly a 5% move around the October 30 earnings release, indicating that investors expect significant volatility as they assess results and forward guidance. AbbVie options and earnings volatility
• Neutral Sentiment: Coverage continues to describe AbbVie as an attractive, income-focused “Dividend King,” although its high earnings multiple makes future performance dependent on sustained earnings growth. AbbVie Dividend King coverage
• Negative Sentiment: Erste Group Bank reduced its EPS forecast and expressed a weak outlook for AbbVie’s fiscal 2026 earnings, creating a counterweight to the favorable product and institutional news. Erste Group lowers AbbVie EPS forecast

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SYM FINANCIAL Corp boosted its stake in AbbVie by 1.0% during the third quarter. SYM FINANCIAL Corp now owns 4,190 shares of the company’s stock worth $1,096,000 after buying an additional 42 shares during the period. Oakworth Capital Inc. increased its position in shares of AbbVie by 1.1% during the third quarter. Oakworth Capital Inc. now owns 12,791 shares of the company’s stock valued at $3,346,000 after acquiring an additional 141 shares during the last quarter. Black Diamond Financial LLC increased its position in shares of AbbVie by 23.9% during the third quarter. Black Diamond Financial LLC now owns 2,420 shares of the company’s stock valued at $633,000 after acquiring an additional 467 shares during the last quarter. DMC Group LLC raised its stake in shares of AbbVie by 2.0% in the 3rd quarter. DMC Group LLC now owns 5,656 shares of the company’s stock valued at $1,480,000 after acquiring an additional 113 shares during the period. Finally, Cahaba Wealth Management Inc. raised its stake in shares of AbbVie by 2.5% in the 3rd quarter. Cahaba Wealth Management Inc. now owns 3,746 shares of the company’s stock valued at $980,000 after acquiring an additional 92 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $286.88 on Friday. AbbVie has a one year low of $190.75 and a one year high of $291.40. The stock has a market cap of $506.85 billion, a PE ratio of 26.28, a P/E/G ratio of 1.30 and a beta of 0.24. The stock has a 50 day moving average price of $266.18 and a 200 day moving average price of $235.62.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie will post 13.93 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.